Application of nano-based systems for drug delivery and targeting: a review
Source abstract
Abstract
Over the last decades, magnificent progress in the field of nanopharmaceuticals mostly with sizes smaller than 100 nm has led to the development of novel delivery systems and brightened the hope of finding new approaches to combat threatening diseases including cancer. So far, numerous efforts have been made to develop appropriate delivery systems with favorable features such as acceptable toxicity profile, high cellular uptake, low immunogenicity, and stable physicochemical properties along with distribution of the therapeutic molecule specifically to the site of action, without affecting healthy organs and tissues. Non-viral delivery systems have always been suitable options for delivery purposes. Polymers, liposomes, and inorganic delivery systems are all of the available choices in non-viral delivery systems, with each possessing their own advantages and pitfalls. This current review presents the recent advances about the application of various non-viral nanocarriers in the delivery of diverse therapeutic agents especially in cancer treatment. Targeting ligands as an important part of designing targeted nanocarriers to the site of interest or intra-cellular environment and opportunities and challenges of nano-based systems for drug and gene delivery are also discussed.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Agashe HB, Dutta T, Garg M, Jain NK (2006) Investigations on the toxicological profile of functionalized fifth-generation poly (propylene imine) dendrimer. J Pharm Pharmacol 58(11):1491–149810.1211/jpp.58.11.0010 ↗
2. Ahmed TA, Aljaeid BM (2016) Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery. Drug Design Dev Ther 10:48310.2147/DDDT.S99651 ↗
3. Ai JW, Liu B, Liu WD (2017) Folic acid-tagged titanium dioxide nanoparticles for enhanced anticancer effect in osteosarcoma cells. Mater Sci Eng C Mater Biol Appl 76:1181–118710.1016/j.msec.2017.03.027 ↗
4. Alexander G, Tkachenko HX, Coleman D, Glomm W, Ryan J, Anderson SF MF, Feldheim DL (2003) Multifunctional gold nanoparticle-peptide complexes for nuclear targeting. Am Chem Soc 125(16):4700–470110.1021/ja0296935 ↗
5. Ali A, Ahmed S (2018) A review on chitosan and its nanocomposites in drug delivery. Int J Biol Macromol 109:273–28610.1016/j.ijbiomac.2017.12.078 ↗
6. Alkilany AM, Thompson LB, Boulos SP, Sisco PN, Murphy CJ (2012) Gold nanorods: their potential for photothermal therapeutics and drug delivery, tempered by the complexity of their biological interactions. Adv Drug Deliv Rev 64(2):190–19910.1016/j.addr.2011.03.005 ↗
7. Alley SC, Okeley NM, Senter PD (2010) Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 14(4):529–53710.1016/j.cbpa.2010.06.170 ↗
8. Almalik A, Donno R, Cadman CJ, Cellesi F, Day PJ, Tirelli N (2013) Hyaluronic acid-coated chitosan nanoparticles: Molecular weight-dependent effects on morphology and hyaluronic acid presentation. J Control Release 172(3):1142–115010.1016/j.jconrel.2013.09.032 ↗
9. Amadou KS, Camara EJL, Stowe DF (2010) Potential therapeutic benefits of strategies directed to mitochondria. Antioxid Redox Signal 13(3):279–34710.1089/ars.2009.2788 ↗
10. Anandhakumar S, Mahalakshmi V, Raichur AM (2012) Silver nanoparticles modified nanocapsules for ultrasonically activated drug delivery. Mater Sci Eng C 32(8):2349–235510.1016/j.msec.2012.07.006 ↗
11. Ansari M, Bigham A, Hassanzadeh-Tabrizi SA, Abbastabar AH (2017) Synthesis and characterization of Cu 0.3 Zn 0.5 Mg 0.2 Fe 2 O 4 nanoparticles as a magnetic drug delivery system. J Magn Magn Mater 439:67–7510.1016/j.jmmm.2017.04.084 ↗
12. Araujo RS, Silveira ALM, de Sales ESEL, Freire RH, de Souza CM, Reis DC et al (2017) Intestinal toxicity evaluation of long-circulating and pH-sensitive liposomes loaded with cisplatin. Eur J Pharm Sci 106:142–15110.1016/j.ejps.2017.05.046 ↗
13. Aungst BJ (2000) Intestinal permeation enhancers. J Pharm Sci 89:429–44210.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J ↗
14. Awad NK, Edwards SL, Morsi YS (2017) A review of TiO2 NTs on Ti metal: electrochemical synthesis, functionalization and potential use as bone implants. Mater Sci Eng C Mater Biol Appl 76:1401–141210.1016/j.msec.2017.02.150 ↗
15. Bahadar H, Maqbool F, Niaz K, Abdollahi M (2016) Toxicity of nanoparticles and an overview of current experimental models. Iran Biomed J 20(1):1
16. Baradaran Eftekhari R, Maghsoudnia N, Samimi S, Abedin DF (2019) Application of chitosan in oral drug delivery. In: Jana S, Jana S (eds) Functional chitosan: drug delivery and biomedical applications. Springer Singapore, Singapore, pp 43–7310.1007/978-981-15-0263-7_2 ↗
17. Baradaran Eftekhari R, Maghsoudnia N, Dorkoosh FA. Chloroquine: a brand-new scenario for an old drug. Taylor & Francis; 202010.1080/17425247.2020.1716729 ↗
18. Biffi S, Voltan R, Bortot B, Zauli G, Secchiero P (2019) Actively targeted nanocarriers for drug delivery to cancer cells. Expert Opin Drug Deliv 16(5):481–49610.1080/17425247.2019.1604679 ↗
19. Biswas S, Dodwadkar NS, Piroyan A, Torchilin VP (2012) Surface conjugation of triphenylphosphonium to target poly(amidoamine) dendrimers to mitochondria. Biomaterials. 33(18):4773–478210.1016/j.biomaterials.2012.03.032 ↗
20. Boisselier E, Astruc D (2009) Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem Soc Rev 38(6):1759–178210.1039/b806051g ↗
21. Brannon-Peppas L, Blanchette JO (2012) Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 64:206–21210.1016/j.addr.2012.09.033 ↗
22. Bugnicourt L, Ladaviere C (2017) A close collaboration of chitosan with lipid colloidal carriers for drug delivery applications. J Control Release 256:121–14010.1016/j.jconrel.2017.04.018 ↗
23. Caoduro C, Hervouet E, Girard-Thernier C, Gharbi T, Boulahdour H, Delage-Mourroux R et al (2017) Carbon nanotubes as gene carriers: focus on internalization pathways related to functionalization and properties. Acta Biomater 49:36–4410.1016/j.actbio.2016.11.013 ↗
24. Cea RJ (1996) Preliminary biological evaluation of polyamidoamine (PAMAM) starburst dendrimers. J Biomed Mater Res 30:53–6510.1002/(SICI)1097-4636(199601)30:1<53::AID-JBM8>3.0.CO;2-Q ↗
25. Chamberlain GR, Tulumello DV, Kelley SO (2013) Targeted delivery of doxorubicin to mitochondria. ACS Chem Biol 8:1389–139510.1021/cb400095v ↗
26. Champion JA, Mitragotri S (2006) Role of target geometry in phagocytosis. Proc Natl Acad Sci 103(13):4930–493410.1073/pnas.0600997103 ↗
27. Chauhan G, Chopra V, Tyagi A, Rath G, Sharma RK, Goyal AK (2017) "Gold nanoparticles composite-folic acid conjugated graphene oxide nanohybrids" for targeted chemo-thermal cancer ablation: in vitro screening and in vivo studies. Eur J Pharm Sci 96:351–36110.1016/j.ejps.2016.10.011 ↗
28. Chen J, Guo Z, Wang HB, Gong M, Kong XK, Xia P et al (2013) Multifunctional Fe3O4@C@Ag hybrid nanoparticles as dual modal imaging probes and near-infrared light-responsive drug delivery platform. Biomaterials. 34(2):571–58110.1016/j.biomaterials.2012.10.002 ↗
29. Chen JX, Wang M, Tian HH, Chen JH (2015) Hyaluronic acid and polyethylenimine self-assembled polyion complexes as pH-sensitive drug carrier for cancer therapy. Colloids Surf B: Biointerfaces 134:81–8710.1016/j.colsurfb.2015.06.039 ↗
30. Chen ZP, Li M, Zhang LJ, He JY, Wu L, Xiao YY et al (2016) Mitochondria-targeted drug delivery system for cancer treatment. J Drug Target 24(6):492–50210.3109/1061186X.2015.1108325 ↗
31. Chen X, Sun H, Hu J, Han X, Liu H, Hu Y (2017a) Transferrin gated mesoporous silica nanoparticles for redox-responsive and targeted drug delivery. Colloids Surf B: Biointerfaces 152:77–8410.1016/j.colsurfb.2017.01.010 ↗
32. Chen K, Guo L, Zhang J, Chen Q, Wang K, Li C et al (2017b) A gene delivery system containing nuclear localization signal: Increased nucleus import and transfection efficiency with the assistance of RanGAP1. Acta Biomater 48:215–22610.1016/j.actbio.2016.11.004 ↗
33. Chen P, Liu Y, Zhao J, Pang X, Zhang P, Hou X et al (2018a) The synthesis of amphiphilic polyethyleneimine/calcium phosphate composites for bispecific T-cell engager based immunogene therapy. Biomaterials science 6(3):633–64110.1039/C7BM01143A ↗
34. Chen C, Li G, Zhang L, Huang X, Cheng D, Wu S et al (2018b) MicroRNA delivery mediated by PEGylated polyethylenimine for prostate cancer therapy. Open Chemistry 16(1):1257–126710.1515/chem-2018-0138 ↗
35. Chereddy KK, Her CH, Comune M, Moia C, Lopes A, Porporato PE et al (2014) PLGA nanoparticles loaded with host defense peptide LL37 promote wound healing. J Control Release 194:138–14710.1016/j.jconrel.2014.08.016 ↗
36. Chi Y, Yin X, Sun K, Feng S, Liu J, Chen D et al (2017) Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models. J Control Release 261:113–12510.1016/j.jconrel.2017.06.027 ↗
37. Cho HJ, Chung M, Shim MS (2015) Engineered photo-responsive materials for near-infrared-triggered drug delivery. J Ind Eng Chem 31:15–2510.1016/j.jiec.2015.07.016 ↗
38. Dai L, Si C-L (2017) Cellulose- graft -poly(methyl methacrylate) nanoparticles with high biocompatibility for hydrophobic anti-cancer drug delivery. Mater Lett 207:213–21610.1016/j.matlet.2017.07.090 ↗
39. Danhier F, Lecouturier N, Vroman B, Jérôme C, Marchand-Brynaert J, Feron O et al (2009) Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release 133(1):11–1710.1016/j.jconrel.2008.09.086 ↗
40. David A, Jans CKC, Huebner S (1998) Signals mediating nuclear targeting and their regulation: application in drug delivery John Wiley & Sons, Inc. Med Res Rev 18(4):189–22310.1002/(SICI)1098-1128(199807)18:4<189::AID-MED1>3.0.CO;2-R ↗
41. De Beuckelaer A, Pollard C, Van Lint S, Roose K, Van Hoecke L, Naessens T et al (2016) Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic t cell responses. Mol Ther 24(11):2012–202010.1038/mt.2016.161 ↗
42. de Groot AM, Du G, Monkare J, Platteel ACM, Broere F, Bouwstra JA et al (2017) Hollow microneedle-mediated intradermal delivery of model vaccine antigen-loaded PLGA nanoparticles elicits protective T cell-mediated immunity to an intracellular bacterium. J Control Release 266:27–3510.1016/j.jconrel.2017.09.017 ↗
43. de la Rica R, Aili D, Stevens MM (2012) Enzyme-responsive nanoparticles for drug release and diagnostics. Adv Drug Deliv Rev 64(11):967–97810.1016/j.addr.2012.01.002 ↗
44. de Villiers MM, Lvov YM (2011) Layer-by-layer self-assembled nanoshells for drug delivery. Adv Drug Deliv Rev 63(9):699–70010.1016/j.addr.2011.06.001 ↗
45. des Rieux A, Pourcelle V, Cani PD, Marchand-Brynaert J, Preat V (2013) Targeted nanoparticles with novel non-peptidic ligands for oral delivery. Adv Drug Deliv Rev 65(6):833–84410.1016/j.addr.2013.01.002 ↗
46. Devulapally R, Lee T, Barghava-Shah A, Sekar TV, Foygel K, Bachawal SV et al (2018) Ultrasound-guided delivery of thymidine kinase–nitroreductase dual therapeutic genes by PEGylated-PLGA/PEI nanoparticles for enhanced triple negative breast cancer therapy. Nanomedicine. 13(9):1051–106610.2217/nnm-2017-0328 ↗
47. Dharap SS, Wang Y, Chandna P, Khandare JJ, Qiu B, Gunaseelan S et al (2005) Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci U S A 102(36):12962–1296710.1073/pnas.0504274102 ↗
48. Dixit N, Vaibhav K, Pandey RS, Jain UK, Katare OP, Katyal A et al (2015) Improved cisplatin delivery in cervical cancer cells by utilizing folate-grafted non-aggregated gelatin nanoparticles. Biomed Pharmacother 69:1–1010.1016/j.biopha.2014.10.016 ↗
49. Dmour I, Taha MO (2017) Novel nanoparticles based on chitosan-dicarboxylate conjugates via tandem ionotropic/covalent crosslinking with tripolyphosphate and subsequent evaluation as drug delivery vehicles. Int J Pharm 529(1–2):15–3110.1016/j.ijpharm.2017.06.061 ↗
50. Dong DW, Tong SW, Qi XR (2013) Comparative studies of polyethylenimine-doxorubicin conjugates with pH-sensitive and pH-insensitive linkers. J Biomed Mater Res A 101(5):1336–134410.1002/jbm.a.34450 ↗
51. Dosio F, Arpicco S, Stella B, Fattal E (2016) Hyaluronic acid for anticancer drug and nucleic acid delivery. Adv Drug Deliv Rev 97:204–23610.1016/j.addr.2015.11.011 ↗
52. Dou Y, Hynynen K, Allen C (2017) To heat or not to heat: Challenges with clinical translation of thermosensitive liposomes. J Control Release 249:63–7310.1016/j.jconrel.2017.01.025 ↗
53. Duncan R, Izzo L (2005) Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 57(15):2215–223710.1016/j.addr.2005.09.019 ↗
54. Dutta T, Jain NK (2007) Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim Biophys Acta 1770(4):681–68610.1016/j.bbagen.2006.12.007 ↗
55. Dutta T, Agashe HB, Garg M, Balakrishnan P, Kabra M, Jain NK (2007) Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J Drug Target 15(1):89–9810.1080/10611860600965914 ↗
56. Eftekhari RB, Maghsoudnia N, Samimi S, Zamzami A, Dorkoosh FA (2019) Co-delivery nanosystems for cancer treatment: a review. Pharm Nanotechnol 7(2):90–11210.2174/2211738507666190321112237 ↗
57. Einmahl S, Behar-Cohen F, Tabatabay C, Savoldelli M, D'Hermies F, Chauvaud D et al (2000) A viscous bioerodible poly (ortho ester) as a new biomaterial for intraocular application. J Biomed Mater Res 50(4):566–57310.1002/(SICI)1097-4636(20000615)50:4<566::AID-JBM12>3.0.CO;2-M ↗
58. El Badawy AM, Silva RG, Morris B, Scheckel KG, Suidan MT, Tolaymat TM (2011) Surface charge-dependent toxicity of silver nanoparticles. Environ Sci Technol 45(1):283–28710.1021/es1034188 ↗
59. Elgadir MA, Uddin MS, Ferdosh S, Adam A, Chowdhury AJK, Sarker MZI (2015) Impact of chitosan composites and chitosan nanoparticle composites on various drug delivery systems: a review. J Food Drug Anal 23(4):619–62910.1016/j.jfda.2014.10.008 ↗
60. Eloy JO, Petrilli R, Chesca DL, Saggioro FP, Lee RJ, Marchetti JM (2017) Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy. Eur J Pharm Biopharm 115:159–16710.1016/j.ejpb.2017.02.020 ↗
61. England RM, Hare JI, Kemmitt PD, Treacher KE, Waring MJ, Barry ST et al (2016) Enhanced cytocompatibility and functional group content of poly(l-lysine) dendrimers by grafting with poly(oxazolines). Polym Chem 7(28):4609–461710.1039/C6PY00478D ↗
62. Ensafi AA, Khoddami E, Nabiyan A, Rezaei B (2017) Study the role of poly(diethyl aminoethyl methacrylate) as a modified and grafted shell for TiO 2 and ZnO nanoparticles, application in flutamide delivery. React Funct Polym 116:1–810.1016/j.reactfunctpolym.2017.04.016 ↗
63. Esfand R, Tomalia DA (2001) Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. DDT. 6:427–43610.1016/S1359-6446(01)01757-3 ↗
64. Fahmy TM, Fong PM, Goyal A, Saltzman WM (2005) Targeted for drug delivery. Mater Today 8(8):18–2610.1016/S1369-7021(05)71033-6 ↗
65. Fan Y, Chen C, Huang Y, Zhang F, Lin G (2017) Study of the pH-sensitive mechanism of tumor-targeting liposomes. Colloids Surf B: Biointerfaces 151:19–2510.1016/j.colsurfb.2016.11.042 ↗
66. Feng M, Lee D, Li P (2006) Intracellular uptake and release of poly(ethyleneimine)-co-poly(methyl methacrylate) nanoparticle/pDNA complexes for gene delivery. Int J Pharm 311(1–2):209–21410.1016/j.ijpharm.2005.12.035 ↗
67. Flak D, Yate L, Nowaczyk G, Jurga S (2017) Hybrid ZnPc@TiO2 nanostructures for targeted photodynamic therapy, bioimaging and doxorubicin delivery. Mater Sci Eng C Mater Biol Appl 78:1072–108510.1016/j.msec.2017.04.107 ↗
68. Florea BI, Meaney C, Junginger HE, Borchard G (2002) Transfection efficiency and toxicity of polyethylenimine in differentiated Calu-3 and nondifferentiated COS-1 cell cultures. AAPS PharmSciTech 4(3):1–1110.1208/ps040312 ↗
69. Fonseca SB, Pereira MP, Mourtada R, Gronda M, Horton KL, Hurren R, Minden MD, Schimmer AD, Kelley SO (2011) Rerouting chlorambucil to mitochondria combats drug deactivation and resistance in cancer cells. Chem Biol 18:445–45310.1016/j.chembiol.2011.02.010 ↗
70. Freimann K, Arukuusk P, Kurrikoff K, Pärnaste L, Raid R, Piirsoo A et al (2018) Formulation of stable and homogeneous cell-penetrating peptide NF55 nanoparticles for efficient gene delivery in vivo. Mol Ther - Nucl Acids 10:28–3510.1016/j.omtn.2017.10.011 ↗
71. Furgeson DY, Yockman JW, Janat MM, Kim SW (2004) Tumor efficacy and biodistribution of linear polyethylenimine-cholesterol/DNA complexes. Mol Ther 9(6):837–84510.1016/j.ymthe.2004.02.014 ↗
72. Ghaffari SB, Sarrafzadeh MH, Fakhroueian Z, Shahriari S, Khorramizadeh MR (2017) Functionalization of ZnO nanoparticles by 3-mercaptopropionic acid for aqueous curcumin delivery: Synthesis, characterization, and anticancer assessment. Mater Sci Eng C Mater Biol Appl 79:465–47210.1016/j.msec.2017.05.065 ↗
73. Ghanghoria R, Kesharwani P, Tekade RK, Jain NK (2016) Targeting luteinizing hormone-releasing hormone: a potential therapeutics to treat gynecological and other cancers. J Control Release 269:277–30110.1016/j.jconrel.2016.11.002 ↗
74. Ghosh P, Han G, De M, Kim CK, Rotello VM (2008) Gold nanoparticles in delivery applications. Adv Drug Deliv Rev 60(11):1307–131510.1016/j.addr.2008.03.016 ↗
75. Giansanti L, Mauceri A, Galantini L, Altieri B, Piozzi A, Mancini G (2016) Glucosylated pH-sensitive liposomes as potential drug delivery systems. Chem Phys Lipids 200:113–11910.1016/j.chemphyslip.2016.08.004 ↗
76. Gillies E, Frechet J (2005) Dendrimers and dendritic polymers in drug delivery. Drug Discov Today 10(1):35–4310.1016/S1359-6446(04)03276-3 ↗
77. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J (2013) Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med 15(2):65–7710.1002/jgm.2698 ↗
78. Goodman CM, McCusker CD, Yilmaz T, Rotello VM (2004) Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjug Chem 15(4):897–90010.1021/bc049951i ↗
79. Gormally MV, McKibben RK, Johal MS, Selassie CR (2009) Controlling tyrosinase activity on charged polyelectrolyte surfaces: a QCM-D analysis. Langmuir. 25(17):10014–1001910.1021/la900751w ↗
80. Grossen P, Witzigmann D, Sieber S, Huwyler J (2017) PEG-PCL-based nanomedicines: a biodegradable drug delivery system and its application. J Control Release 260:46–6010.1016/j.jconrel.2017.05.028 ↗
81. Gu L, He X, Wu Z (2014) Mesoporous Fe3O4/hydroxyapatite composite for targeted drug delivery. Mater Res Bull 59:65–6810.1016/j.materresbull.2014.06.018 ↗
82. Guo Q, Li C, Zhou W, Chen X, Zhang Y, Lu Y et al (2019) GLUT1-mediated effective anti-miRNA21 pompon for cancer therapy. Acta Pharm Sin B 9(4):832–84210.1016/j.apsb.2019.01.012 ↗
83. Gusachenko Simonova O, Kravchuk Y, Konevets D, Silnikov V, Vlassov VV, Zenkova MA (2009) Transfection efficiency of 25-kDa PEI-cholesterol conjugates with different levels of modification. J Biomater Sci Polym Ed 20(7–8):1091–111010.1163/156856209X444448 ↗
84. Hadipour Moghaddam SP, Saikia J, Yazdimamaghani M, Ghandehari H (2017) Redox-Responsive polysulfide-based biodegradable organosilica nanoparticles for delivery of bioactive agents. ACS Appl Mater Interfaces 9(25):21133–2114610.1021/acsami.7b04351 ↗
85. Haensler JaS FC Jr (1993) Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug Chem 4:372–37910.1021/bc00023a012 ↗
86. Han J, Na K (2019) Transfection of the TRAIL gene into human mesenchymal stem cells using biocompatible polyethyleneimine carbon dots for cancer gene therapy. J Ind Eng Chem 80:722–72810.1016/j.jiec.2019.02.015 ↗
87. Han HS, Lee J, Kim HR, Chae SY, Kim M, Saravanakumar G et al (2013) Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: mineralization and its effect on tumor targetability in vivo. J Control Release 168(2):105–11410.1016/j.jconrel.2013.02.022 ↗
88. Hao Y, Gao Y, Wu Y, An C (2019) The AIB1siRNA-loaded hyaluronic acid-assembled PEI/heparin/Ca2+ nanocomplex as a novel therapeutic strategy in lung cancer treatment. Int J Mol Med 43(2):861–867
89. Hazekawa M, Nishinakagawa T, Kawakubo-Yasukochi T, Nakashima M (2019) Glypican-3 gene silencing for ovarian cancer using siRNA-PLGA hybrid micelles in a murine peritoneal dissemination model. J Pharmacol Sci 139(3):231–23910.1016/j.jphs.2019.01.009 ↗
90. Heo K, Min SW, Sung HJ, Kim HG, Kim HJ, Kim YH et al (2016) An aptamer-antibody complex (oligobody) as a novel delivery platform for targeted cancer therapies. J Control Release 229:1–910.1016/j.jconrel.2016.03.006 ↗
91. Her S, Jaffray DA, Allen C (2017) Gold nanoparticles for applications in cancer radiotherapy: mechanisms and recent advancements. Adv Drug Deliv Rev 109:84–10110.1016/j.addr.2015.12.012 ↗
92. Howard KA, Rahbek UL, Liu X, Damgaard CK, Glud SZ, Andersen MO et al (2006) RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther 14(4):476–48410.1016/j.ymthe.2006.04.010 ↗
93. Hsu H-L, Chen J-P (2017) Preparation of thermosensitive magnetic liposome encapsulated recombinant tissue plasminogen activator for targeted thrombolysis. J Magn Magn Mater 427:188–19410.1016/j.jmmm.2016.10.122 ↗
94. Hu Y, Xie J, Tong YW, Wang C-H (2007) Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. J Control Release 118(1):7–1710.1016/j.jconrel.2006.11.028 ↗
95. Huang H-C, Barua S, Sharma G, Dey SK, Rege K (2011) Inorganic nanoparticles for cancer imaging and therapy. J Control Release 155(3):344–35710.1016/j.jconrel.2011.06.004 ↗
96. Huang J, Gou G, Xue B, Yan Q, Sun Y, Dong LE (2013) Preparation and characterization of "dextran-magnetic layered double hydroxide-fluorouracil" targeted liposomes. Int J Pharm 450(1–2):323–33010.1016/j.ijpharm.2013.04.010 ↗
97. Huo S, Jin S, Ma X, Xue X, Yang K, Kumar A et al (2014) Ultrasmall gold nanoparticles as carriers for nucleus-based gene therapy due to size-dependent nuclear entry. ACS Nano 8(6):5852–586210.1021/nn5008572 ↗
98. Iaboni M, Russo V, Fontanella R, Roscigno G, Fiore D, Donnarumma E et al (2016) Aptamer-miRNA-212 conjugate sensitizes NSCLC cells to TRAIL. Mol Ther Nucleic Acids 5:e28910.1038/mtna.2016.5 ↗
99. Iannazzo D, Pistone A, Salamo M, Galvagno S, Romeo R, Giofre SV et al (2017) Graphene quantum dots for cancer targeted drug delivery. Int J Pharm 518(1–2):185–19210.1016/j.ijpharm.2016.12.060 ↗
100. Ishida T, Ichihara M, Wang X, Kiwada H (2006) Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J Control Release 115(3):243–25010.1016/j.jconrel.2006.08.001 ↗